Physician profile
Christopher David Easley
NPI 1174067136
$3,403.66
in general payments reported to CMS, 2019-2025
21 companies · $733 in 2025
The $733 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $120 · 2021: $266 · 2022: $792 · 2023: $603 · 2024: $682 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.62 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $761.60 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $450.22 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $409.12 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $311.06 | 2020-2023 | |
| Oyster Point Pharma, INC. | $268.09 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $199.17 | 2019-2025 | |
| Notal Vision, INC. | $190.20 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $143.92 | 2019-2022 | |
| Glaukos Corporation | $129.83 | 2023-2025 | Idose, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Alcon Vision LLC | $110.41 | 2024 | Hydrus Microstent |
| Sight Sciences, INC. | $92.83 | 2021 | |
| Harrow Eye, LLC | $65.41 | 2025 | Vevye |
| Amgen INC. | $54.28 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $44.85 | 2021 | |
| Carl Zeiss Meditec Ag | $34.40 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $32.08 | 2021-2024 | Oxervate |
| Rxsight INC | $26.41 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Horizon Therapeutics Plc | $25.58 | 2023 | Tepezza |
| Allergan, INC. | $23.51 | 2022 | |
| Abbvie INC. | $16.37 | 2023 | Vuity |
| Johnson & Johnson Vision Care, INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Easley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.